Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients

Highlighting the critical role of Caris GPSai in improving cancer care

IRVING, Texas, March 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published a study in JAMA Network Open, titled "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins." This study builds on the body of evidence showing the superiority of Caris' proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types. 

This paper demonstrates that by including AI algorithms as part of routine comprehensive molecular profiling, clinicians can uncover clinically significant misdiagnoses in cases labeled as lung squamous cell carcinoma (SCC), influencing treatment decisions and patient outcomes. The study comprised 3,958 lung cancer cases submitted to Caris with a diagnosis of SCC. Caris GPSai® identified 123 of the 3,958 cases were metastases from other primary sites, including cutaneous, urothelial, head and neck and thymic cancers.

The clinical impact of reclassification underscores the power of precision medicine. The study identified 88 patients (71.5%) who had guideline-preferred first-line systemic therapy change recommendations, alerting clinicians that a change in their patients' treatments would achieve better outcomes. According to the CDC website, lung SCC accounts for roughly 21% of all lung cancer cases in the United States. Applying study-specific stats to the wider CDC data for lung cancer in the United States suggests that approximately 1,000 cases each year may be potential misdiagnoses.

"Caris GPSai has overturned 3,857 diagnoses across the spectrum of cancer since January of 2024," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. "By integrating AI-driven tissue‑of‑origin predictions with comprehensive molecular profiling and pathology, we can give clinicians greater diagnostic confidence and ensure patients receive the most appropriate care."

These misdiagnoses carry direct and life-altering clinical consequences, as treatment recommendations and prognostic expectations differ significantly across cancer types. By embedding Caris GPSai into Caris' comprehensive molecular profiling, providers gain an additional layer of insight that can help patients get the healthcare they deserve.

The GPSai algorithm is included as part of MI Cancer Seek® and MI Tumor Seek® at no additional cost. Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606

SOURCE Caris Life Sciences